, Senator Lee, our staff, his staff who have worked well together. As well as Senator Grassley who is with us. Who has been such a leader when it comes to this competition issues. Thank you for being here, Senator Grassley. This is the latest in the Competition Policy Committee hearings, examining american monopoly problems. Today, we will focus on the lack of competition in our Prescription Drug markets. The stakes could not be higher. According to the center for care services, Health Care Spending accounted for 17. 7 percent of growth in 2019. More than 16 of the american economy. That is projected to rise to 19. 7 by 2028. Rising Prescription Drug prices is a key driver in those numbers. But, it is not just about gdp. It is also about the all too real human cost we will hear about today. For some, the ability to access Prescription Drugs is what enables them to work, care for their families and loved ones. To just get through the day without excruciating pain. For others, access to
This hearing runs two hours and 15 minutes. [inaudible] [inaudible conversations] [inaudible conversations] [inaudible conversations] i want to thank my colleague and our staff and his staff who work very well together as well as Senator Grassley who has been such a leader when it comes to these competition Issues Way before ites was cool so thank yu for being here, Senator Grassley. This is the latest in the Subcommittee Series of hearings examining americas monopoly problem. Today we are going to focus on the lack of competition in the Prescription Drug markets. The stakes could not be higher according to the centers of Medicaid And Medicare services, Healthcare Spending accounted for 17. 7 of u. S. Gross domestic products in 2019. That is more than 16 of the american economy. That is projected to rise to 19. 7 by 2028. And rising Prescription Drug prices is a key driver in those numbers but it isnt just about gdp. Its also about the all too real human cost that we will hear about to
, Senator Lee, our staff, his staff who have worked well together. As well as Senator Grassley who is with us. Who has been such a leader when it comes to this competition issues. Thank you for being here, Senator Grassley. This is the latest in the Competition Policy Committee hearings, examining american monopoly problems. Today, we will focus on the lack of competition in our Prescription Drug markets. The stakes could not be higher. According to the center for care services, Health Care Spending accounted for 17. 7 percent of growth in 2019. More than 16 of the american economy. That is projected to rise to 19. 7 by 2028. Rising Prescription Drug prices is a key driver in those numbers. But, it is not just about gdp. It is also about the all too real human cost we will hear about today. For some, the ability to access Prescription Drugs is what enables them to work, care for their families and loved ones. To just get through the day without excruciating pain. For others, access to